Skip to main content

Table 5 Neurologic diseases treated with both intravenous immunoglobulin infusion and therapeutic plasma exchange

From: Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome

Neurologic Disease

Role of intravenous immunoglobulin infusion in treatment [33]

Role of therapeutic plasma exchange in treatment [13]

Acute inflammatory demyelinating polyneuropathy (AIDP, Guillain-Barré syndrome)

Definite

First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A)

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Definite

First line therapy with a strong recommendation and moderate quality evidence. (Category I, Recommendation grade 1B)

Lambert-Eaton myasthenic syndrome (LEMS)

Probable

Second line therapy with a weak recommendation and low quality or very low quality evidence. (Category II, Recommendation grade 2C)

IgM anti-myelin associated glycoprotein paraprotein associated peripheral neuropathy

Probable

First line therapy with a strong recommendation and low quality or very low quality evidence. (Category I, Recommendation grade 1C)

Myasthenia gravis (MG)

Probable

First line therapy with a strong recommendation and high-quality evidence. (Category I, Recommendation grade 1A)

Multiple sclerosis (MS)

Possible

Second line therapy with a strong recommendation and moderate quality evidence. (Category II, Recommendation grade 1B)

Acute disseminated encephalomyelitis (ADEM)

Possible

Second line therapy with a weak recommendation and moderate quality evidence. (Category II, Recommendation grade 2C)